Bruker Expands Proteomics Capabilities with New Software at US HUPO At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in 4D-Proteomics™ performance, software, and applications to enhance biological insights. These new developments aim to refine…
Samsung Bioepis Co., Ltd. has announced the official U.S. launch of PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), expanding treatment options for patients with inflammatory conditions. This development marks a significant milestone in the biosimilars market and further solidifies Samsung…
Estrella Immunopharma Advances STARLIGHT-1 Trial to Higher Dose Cohort Following Successful Initial Results Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative CD19-targeted ARTEMIS® T-cell therapies for the treatment of cancer…
Go Reply and Sprint Reply Automate Clinical Study Report Generation for Dr. Willmar Schwabe Using AI In a groundbreaking collaboration, Go Reply, a leading Google Cloud Premier Partner, and Sprint Reply, the Reply Group’s expert in strategic consulting and digital…
New International Guidelines Released for the Treatment of Candida Fungal Infections A groundbreaking global guideline for the diagnosis and treatment of Candida infections has been published in The Lancet Infectious Diseases. This comprehensive guideline establishes new standards for the management…
Alzamend Neuro Advances Alzheimer’s and Psychiatric Disorder Research with Tesla-Developed Head Coil for Phase II Trials Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and psychiatric disorders, has announced the completion…
Stablepharma Secures Prestigious €2.5 Million EIC Accelerator Grant, Recognised Among Europe’s Leading Innovators UK-based biotechnology company Stablepharma Ltd has secured €2.5 million in funding from the highly competitive European Innovation Council (EIC) Accelerator program. This significant achievement highlights the company’s…
InnoCare Gets Approval for Phase III Study of ICP-248 and Orelabrutinib for First-Line CLL/SLL Therapy in China InnoCare Pharma, a prominent biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, has made a significant announcement regarding the approval…
FDA Approves GSK’s PENMENVY, a 5-in-1 Meningococcal Vaccine for MenABCWY Protection GSK plc has announced that the U.S. Food and Drug Administration (FDA) has granted approval for PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in…
Galderma (SWX:GALD) has announced that the European Commission has granted approval for Nemluvio, a groundbreaking biologic therapy, for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis within the European Union (EU). This regulatory milestone paves the way for Nemluvio…
Tempus Partners with IFLI to Advance Development of Targeted Therapies for Follicular Lymphoma Tempus AI, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Join Forces to Accelerate Development of Targeted Therapies for Follicular Lymphoma Tempus AI, Inc., a pioneering…
Ensoma Secures Rare Pediatric Disease & Orphan Drug Status for EN-374 in Chronic Granulomatous Disease Ensoma, a genomic medicines company pioneering in vivo therapies to engineer the hematopoietic system, has announced that the U.S. Food and Drug Administration (FDA) has…